# Spero Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spero-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.sperotherapeutics.com
- Total disclosed funding: $112M
- Latest round: Series C (Mar 8, 2017)
- Investors on record: 10

## About

Spero Therapeutics, Inc. is a biopharmaceutical company based in the US that develops innovative therapies focusing on rare diseases and multidrug-resistant bacterial infections through advanced antibiotic solutions.Founded in 2013, Spero Therapeutics, Inc. is engaged in developing treatments for patients with complex infections. The company, headquartered in Cambridge, US, was co-founded by Ankit Mahadevia, Laurence Rahme, and Milind Deshpande. Its latest funding round in November 2017 raised USD 40.00 mn from Pfizer Inc., bringing the total amount raised to USD 40.00 mn through 10 deals.Spero Therapeutics primarily focuses on creating innovative therapies for patients with rare diseases and multidrug-resistant bacterial infections. The core product, Tebipenem HBr, is an investigational oral carbapenem antibiotic intended for treating complicated urinary tract infections (cUTIs). This product aims to prevent hospitalizations and reduce inpatient therapy durations, addressing significant gaps in available oral treatment options in the US.For the year 2024, Spero Therapeutics reported a revenue of USD 47.98 mn and an EBITDA of USD -73.36 mn. The company's revenue model is driven by partnerships and potential product commercialization following regulatory approvals.Spero Therapeutics plans to advance the development of Tebipenem HBr and other future products designed to target rare diseases and multidrug-resistant infections. The recent funding will support these initiatives as the company aims to establish agreements with healthcare institutions and expand its market presence. The management seeks to enter new geographic markets to enhance patient access to effective treatments.

## Funding rounds

- Series C, Mar 8, 2017, $52M — Atlas Venture, SR One, OUP (Osage University Partners), Merck Global Health Innovation Fund, GV, Lundbeckfond Ventures, Kraft Group, RA Capital Management, Rock Springs Capital
- Series B, Feb 2, 2016, $30M — Atlas Venture, SR One, Merck Global Health Innovation Fund, Lundbeckfond Ventures, Mass General Brigham Ventures, Kraft Group
- Series A, Jun 8, 2015, $30M — Atlas Venture, SR One, Merck Global Health Innovation Fund, Lundbeckfond Ventures, Mass General Brigham Ventures, Kraft Group

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B, Series C
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A, Series B, Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B, Series C
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- Kraft Group — Series A, Series B, Series C
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series C
- GV (https://capitalatlas.ai/funds/gv) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C